BRAF and melanoma: Although immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors have transformed melanoma management and significantly improved patient survival, treating unresectable NAM remains challenging due to the low frequency of BRAF mutations and resistance to immunotherapy [19, 24–34].